Andrew Stevens

Vice President-Clinical & Regulatory Affairs at ViRexx Medical Corp.

Andrew Stevens

Andrew Stevens

Vice President-Clinical & Regulatory Affairs at ViRexx Medical Corp.

Biography

Andrew Stevens is Vice President of Clinical/Regulatory for ViRexx Medical Corp. Prior to joining ViRexx, he was Vice President of Product Development at Cytovax, Inc. Previously, he was Vice President of Clinical Research and Regulatory Affairs with ViRexx and Director of Clinical and Regulatory Affairs and Director of Clinical and Professional Affairs at Biomira, Inc. Dr. Stevens holds a BS in Pharmacy and a PhD in Bionucleonics.

Overview
RelSci Relationships

13

Relationships
RelSci Relationships are individuals Andrew Stevens likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Operating Officer at ViRexx Medical Corp.

Relationship likelihood: Average

Director-Business Development at ViRexx Medical Corp.

Relationship likelihood: Average

Founder at Akshaya Bio, Inc.

Relationship likelihood: Average

Chief Operating Officer at IM Biotechnologies Ltd.

Relationship likelihood: Average

Partner at Parlee Mclaws LLP

Relationship likelihood: Average

Manager-Finance at ViRexx Medical Corp.

Relationship likelihood: Average

Former Chief Financial Officer at GDI Integrated Facility Services, Inc.

Relationship likelihood: Average

President & Chief Executive Officer at Isuma Strategies, Inc.

Relationship likelihood: Weak

Former President & Chief Operating Officer at ViRexx Medical Corp.

Relationship likelihood: Weak

Chief Financial Officer at Maricann Group, Inc.

Relationship likelihood: Weak

Paths to Andrew Stevens
Potential Connections via
Relationship Science
You
Andrew Stevens
Vice President-Clinical & Regulatory Affairs at ViRexx Medical Corp.
Career History
Vice President-Clinical & Regulatory Affairs
Current

The Group's principal activity is to conduct research, develop and commercialize biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, leading to tumor tissue starvation and death.

Other Affiliations

Andrew Stevens is affiliated with ViRexx Medical Corp.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Andrew Stevens. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Andrew Stevens's profile does not indicate a business or promotional relationship of any kind between RelSci and Andrew Stevens.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/andrew-stevens-3481674
  • https://relationshipscience.com/person/andrew-stevens-3481674